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PCLINICAL RESEARCH Clinical Trials
Effects of Telmisartan Added to
Angiotensin-Converting Enzyme Inhibitors
on Mortality and Morbidity in Hemodialysis Patients
With Chronic Heart Failure
A Double-Blind, Placebo-Controlled Trial
Gennaro Cice, MD,* Attilio Di Benedetto, MD,† Salvatore D’Isa, MD,*‡ Antonello D’Andrea, MD,*
Daniele Marcelli, MD,§ Emanuele Gatti, MD,§ Raffaele Calabrò, MD*
Naples and Rome, Italy; and Bad Homburg, Germany
Objectives The aim of this study was to determine whether telmisartan decreases all-cause and cardiovascular mortality
and morbidity in hemodialysis patients with chronic heart failure (CHF) and impaired left ventricular ejection
fraction (LVEF) when added to standard therapies with angiotensin-converting enzyme inhibitors.
Background In hemodialysis patients, CHF is responsible for a high mortality rate, but presently very few data are available
with regard to this population.
Methods A 3-year randomized, double-blind, placebo-controlled, multicenter trial was performed involving 30 Italian clinics.
Hemodialysis patients with CHF (New York Heart Association functional class II to III; LVEF 40%) were randomized
to telmisartan or placebo in addition to angiotensin-converting enzyme inhibitor therapy. A total of 332 patients were
enrolled (165 telmisartan, 167 placebo). Drug dosage was titrated to a target dose of telmisartan of 80 mg or pla-
cebo. Mean follow-up period was 35.5  8.5 months (median: 36 months; range: 2 to 40 months). Primary out-
comes were: 1) all-cause mortality; 2) cardiovascular mortality; and 3) CHF hospital stay.
Results At 3 years, telmisartan significantly reduced all-cause mortality (35.1% vs. 54.4%; p  0.001), cardiovascular
death (30.3% vs. 43.7%; p  0.001), and hospital admission for CHF (33.9% vs. 55.1%; p  0.0001). With Cox
proportional hazards analysis, telmisartan was an independent determinant of all-cause mortality (hazard ratio
[HR]: 0.51; 95% confidence interval [CI]: 0.32 to 0.82; p  0.01), cardiovascular mortality (HR: 0.42; 95% CI:
0.38 to 0.61; p  0.0001), and hospital stay for deterioration of heart failure (HR: 0.38; 95% CI: 0.19 to 0.51;
p  0.0001). Adverse effects, mainly hypotension, occurred in 16.3% of the telmisartan group versus 10.7% in
the placebo group.
Conclusions Addition of telmisartan to standard therapies significantly reduces all-cause mortality, cardiovascular death, and
heart failure hospital stays in hemodialysis patients with CHF and LVEF 40%. (Effects Of Telmisartan Added To
Angiotensin Converting Enzyme Inhibitors On Mortality And Morbidity In Haemodialysed Patients With Chronic
Heart Failure: A Double-Blind Placebo-Controlled Trial; NCT00490958). (J Am Coll Cardiol 2010;56:1701–8)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.105e
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sp to 64% of patients with end-stage renal disease (ESRD)
ave evidence of chronic heart failure (CHF). In hemodi-
lysis patients, CHF is responsible for high rates of mor-
ality and morbidity (1). Although the treatment of patients
ith CHF in the general population (2–9) is well-
rom the *Second University of Naples, Naples, Italy; †NephroCare Italy, Naples, Italy;
IRCCS San Raffaele Pisana, Rome, Italy; and §Fresenius Medical Care, Bad Homburg,
ermany. All authors have reported that they have no relationships to disclose.s
Manuscript received November 9, 2009; revised manuscript received March 3,
010, accepted March 18, 2010.stablished, few data are presently available on patients with
HF on hemodialysis treatment. In fact, it is generally
ssumed that the effect and the dosage of a given drug,
See page 1709
alidated in the general population, can be extended to
remic patients. However, this is not necessarily true and
hould rather be demonstrated in appropriate studies.
Angiotensin II type 1 receptor blockers (ARB) have been
hown to have favorable effects on hemodynamic measure-
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Telmisartan in Hemodialysis Patients With CHF November 16, 2010:1701–8ments, neurohumoral activity, left-
ventricular remodelling, mortality,
and morbidity when added to
angiotensin-converting enzyme
inhibitors (ACE-I) in patients
with CHF (9 –11).
Among ARBs, telmisartan has
distinctive angiotensin II type 1
receptor-binding properties: high
affinity and slow dissociation; a
half-life of approximately 24 h;
high plasma protein binding; and
a distribution volume of approx-
imately 500 l, indicating addi-
tional tissue binding (12).
On these grounds, the aim of the
present study was to determine—
in a randomized, double-blind,
placebo-controlled, multicenter
trial—whether a combination of
an ARB, namely telmisartan, and
standard therapies including ACE-I
and beta-blockers (BB) decreases
ll-cause mortality, cardiovascular mortality, and morbidity in
emodialysis patients with CHF and impaired left ventricular
jection fraction (LVEF).
ethods
ata were collected in 30 Italian clinics of a dialysis provider
etwork with a prospective database (European Clinical
atabase), the main purpose of which is the support of
uality assurance (13). Participating centers are listed in the
nline Appendix. Clinical Trial Ethical Review Committee
pproval was granted at all participating centers. Each
atient provided written informed consent before random-
zation. The trial was registered with Clinicaltrials.gov
NCT00490958).
We enrolled 351 patients that matched the inclusion
riteria: adult hemodialysis patients with CHF; New York
eart Association (NYHA) functional class II and III;
jection fraction 40% determined within 6 months; and
herapy with ACE-I individually optimized and unchanged
or 30 days before randomization. The use of other
onventional heart failure treatments, including BB and
igitalis, was recommended when appropriate. Discontinu-
tion of these agents or the study drug was left to the
iscretion of the physicians; the reasons for discontinuation
ere documented, and patients were subsequently observed
or outcomes. The recruitment period was from January
999 to January 2003.
All patients were dialyzed 4/week. In our population,
2.2% of the patients had an artero-venous fistula. The “dry
eight” for all patients was stable for at least 1 month. The
Abbreviations
and Acronyms
ACE-I  angiotensin-
converting enzyme inhibitor
ARB  angiotensin II type 1
receptor blocker
BB  beta-blocker
CHF  chronic heart failure
CI  confidence interval
ESRD  end-stage renal
disease
HR  hazard ratio
LVDd  left ventricular
internal diastolic diameter
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
NYHA  New York Heart
Association
RAAS  renin-angiotensin-
aldosterone systemrterial pressure values reported in our study refer to the dre-dialysis period. Epoetin therapy was administered when
ecessary to maintain a mean hemoglobin value of 11.5 
.5 g/dl.
Plasma potassium levels were checked in all patients at
he beginning of each dialysis treatment. Possible changes in
lasma potassium concentration were controlled by modu-
ating potassium intake and type of hemodialysis and by
educing blood acidosis.
The trial profile is illustrated in Figure 1. During a
reliminary “run-in” phase, all patients received telmisartan
20 mg/day) for 2 weeks to determine, before randomiza-
ion, whether any of the patients had a low tolerance to
mall doses of the drug. The run-in phase was necessary,
ecause dialysis patients often experience intradialytic hy-
otension also due to low-dose drugs. Of the 351 enrolled
atients, 19 (5.4%) did not complete the first “run-in” phase
ither because of adverse reactions (7 for symptomatic
ypotension, 1 for diarrhea, 1 for flushing) or due to
dministrative reasons (4 for withdrawal of consent, 6 for
hange in dialysis center). The final population of 332
SRD patients was randomized to telmisartan (n 165) or
lacebo (n 167) in addition to ACE-I therapy. Allocation
o the telmisartan or the placebo treatment group was
onducted randomly by a computer-generated assignment
rogram and communicated through a coordinating tele-
hone center. The assignment code was held at an inde-
endent site under control of the Data Safety Monitoring
ommittee.
The dose of the study drug was doubled, as tolerated,
very 2 weeks while aiming for the target dose of 80 mg/day.
fter randomization, clinical observations and monitoring
f blood pressure, serum creatinine, and serum potassium
ere performed 4/week before starting each dialysis ses-
ion. Serial echocardiographic measurements of left ventric-
lar internal diastolic diameter (LVDd) and LVEF were
lso recorded and were performed on non-dialysis day every
months. The mean follow-up period was 35.5  8.5
onths (median: 36 months; range: 2 to 40 months).
The primary outcomes for the present analysis were:
) all-cause mortality; 2) cardiovascular death; and 3) hospital
dmission for management of worsening CHF. Pre-
pecified secondary outcomes included: acute nonfatal
yocardial infarction (MI), combined end point (cardio-
ascular mortality in addition to acute nonfatal MI),
ardiovascular hospital admission, nonfatal stroke, coro-
ary revascularization, and permanent premature treat-
ent withdrawals.
Critical events were classified according to strict defini-
ions. Diagnosis of acute nonfatal MI included the presence
f standard myocardial necrosis biomarkers and typical
lectrocardiograph changes in a clinical setting compatible
ith MI. Pump failure death was defined as death due to
rogressive deterioration of heart failure, acute pulmonary
dema, or cardiogenic shock. Death was recorded as noncar-
iovascular if cardiovascular events were excluded as cause of
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November 16, 2010:1701–8 Telmisartan in Hemodialysis Patients With CHFeath. Death was classified as due to unknown cause when
here was insufficient evidence to confirm the cardiovascular or
oncardiovascular cause.
A CHF hospital admission was defined as admission to
ospital necessitated by heart failure and primarily for its
reatment or when heart failure was a major component of
he hospital admission of the patient. A patient admitted to
hospital for CHF decompensation had to have docu-
ented signs and symptoms of worsening heart failure
equiring intravenous drug administration and a supple-
entary hemodialysis treatment.
tatistical analysis. An annual event rate of 20% for the
rimary end point (all-cause mortality) was expected in
atients with ESRD, on the basis of previous reports. As a
onsequence, a total sample of at least 240 patients (120/
roup) was required to detect a 10% decrease of the event
ate in the group of patients taking telmisartan with a
-tailed test with a significance level of 5%, a power level of
0%, a drop-out rate of 5%, and a total follow-up period of
6 months. However, in our study protocol nearly 100 more
atients were enrolled than the calculated sample size. This
igher number of patients enrolled was decided because of
he possible event of transfers of these patients to other
Figure 1 Trial Profile
Of the 351 eligible patients (pts), 19 were excluded during the run-in phase.
The remaining 332 patients were randomly allocated to receive telmisartan or
placebo. ESRD  end-stage renal disease.enters or protocol violation. tData are presented as mean  SD. Descriptive statistics
rocedures were used to analyze the distribution of each
ariable. Samples were tested for normal distribution with
he Box-Bartlett homogeneity test, skew analysis (that
easures the asymmetry of the distribution) and kurtosis
nalysis (that shows the extent to which observations cluster
round a central point). In this study, continuous variables
howed a normal distribution. The analysis was carried out
n an intention-to-treat basis and included all randomized
atients. Patient groups were compared by paired and
npaired Student t test for continuous variables and the
hi-square test for categorical variables. Multivariable Cox
roportional hazard regression models were performed to
eigh the independent effects of potential determinants on
dependent variable. The following variables were included
nto the analysis: clinical data (age, sex, pre-dialysis systolic
lood pressure, heart rate, diabetes mellitus, previous MI),
tandard echocardiographic indexes (LVEF), and laboratory
easurements (hemoglobin, albumin, parathormone). The
.05 probability level was adopted to indicate the signifi-
ance of the association between predictive variables and
vents. The risk associated with a given variable was
xpressed by a hazard ratio (HR) with corresponding 95%
onfidence intervals (CIs). In the multivariable analysis, an
utomatic backward stepwise procedure was adopted. The
umulative probability of freedom from cardiac events was
alculated with Kaplan-Meier life-table analysis and com-
ared between groups with the log-rank test.
The software packages were SPSS for Windows release
2.0 (SPSS, Inc., Chicago, Illinois) and Clinical Trial
imulator (CTS) (IcebergSim version 3.06 beta, Practihc
oordinating Office, Oslo, Norway).
atient characteristics and treatment. Clinical features of
he 351 patients enrolled in the study, including details of
heir background medical treatment, are shown in Table 1.
t the time of randomization, overall, approximately two-
hirds of patients (66.5%) were NYHA functional class II,
nd one-third (33.5%) were NYHA functional class III.
The 2 groups (telmisartan or placebo) were comparable
or all the clinical variables considered. No significant
ifferences were evidenced at baseline in LV internal dia-
tolic diameter and LVEF.
All patients were taking ACE-I—enalapril or ramipril in
4% of patients, mean daily dose of 18.6 mg and of 8.9 mg,
espectively, similar to that reached in a previous trial (14)
nd without significant differences in either group. Further-
ore, 60.3% of telmisartan patients and 61.6% of placebo
atients were receiving carvedilol, the only BB used, as
reviously described (15), at a similar mean dose in the 2
roups (mean 46 mg/day). The mean daily dose of the study
rug was 75.2 mg in the telmisartan group and a putative
8.3 mg in the placebo group. The target dose of 80 mg/day
as reached in 76% of the telmisartan group.
No patient had an implantable defibrillator or a biven-ricular pacemaker.
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Telmisartan in Hemodialysis Patients With CHF November 16, 2010:1701–8esults
ortality. During the 3-year follow-up, telmisartan signif-
cantly reduced all-cause mortality (n  58, 35.1% vs. n 
1, 54.4%; p  0.001). Furthermore, there were signifi-
antly fewer cardiovascular deaths in the telmisartan group
n 50, 30.3% vs. n 73, 43.7%; p 0.001). In particular,
he number of pump failure deaths and sudden cardiac
eaths was significantly reduced in patients receiving telm-
sartan (n  34, 20.6% vs. n  52, 31.1%; p  0.0005 for
ump failure mortality; and n  12, 7% vs. n  18, 10.8%
 0.01 for sudden cardiac death), whereas the number of
onfatal MIs, unknown causes of death, and noncardiovas-
ular deaths did not significantly differ between the 2
roups. According to Cox proportional hazards regression
nalysis, after adjustment for clinical, echocardiographic,
nd laboratory variables, the use of telmisartan seemed to be
strong independent predictor for reduction in both all-
ause mortality (HR: 0.51; 95% CI: 0.32 to 0.82; p 0.005)
nd cardiovascular mortality (HR: 0.42; 95% CI: 0.38 to
aseline Characteristics of the Study PopulationTable 1 Baseline Characteristics of the Study Population
Telmisartan
(n  165)
Placebo
(n  167) p Value
Age, yrs 62.7 14.2 62.8 14.6 NS
Male, n 88.0 91.0 NS
Time on dialysis, months 93.6 16.4 94.3 15.8 NS
Body surface area, m2 1.87 0.12 1.89 0.11 NS
Delta body weight, kg 2.8 0.8 2.7 0.8 NS
Diabetic 28.4 29.6 NS
Previous MI 57.3 56.5 NS
Smoking current 12.7 11.3 NS
Smoking previous 26.5 27.4 NS
HR, beats/min 67.1 8.8 68.5 8.4 NS
Pre-dialysis SBP, mm Hg 124.5 8.3 126.3 7.9 NS
Pre-dialysis DBP, mm Hg 82.6 6.2 79.4 6.7 NS
LVDd, cm/m2 3.7 0.5 3.6 0.6 NS
LVEF 30.4 7.5 29.2 7.8 NS
NYHA functional class I 0 0 NS
NYHA functional class II 32.4 34.6 NS
NYHA functional class III 67.6 65.4 NS
NYHA functional class IV 0 0 NS
Hemoglobin, g/dl 11.3 0.7 11.5 0.6 NS
Albumin, g/dl 3.94 0.64 3.89 0.52 NS
PTH, ng/l 251.5 33.6 240.3 38.4 NS
Current treatment
ACE-I 100.0 100.0 NS
Digitalis 53.2 49.8 NS
Beta-blockers 60.3 61.6 NS
Nitrates 48.4 47.6 NS
Statin 67.5 68.4 NS
Amiodarone 19.6 18.7 NS
Aspirin 63.5 64.2 NS
Other antiplatelet agents 32.4 33.1 NS
alues are mean  SD or percentages.
ACI-I  angiotensin-converting enzyme inhibitors; DBP  diastolic blood pressure; LVDd  left
entricular internal diastolic diameter; MI  myocardial infarction; NYHA  New York Heart
ssociation functional class; PTH  parathormone; SBP  systolic blood pressure..61; p  0.0001) (Table 2). iThe cumulative 3-year mean survival time was 30.6
onths in the telmisartan group and 24.2 months in the
lacebo group (log-rank: 13.7; p  0.001) (Fig. 2). In
ddition, patients receiving telmisartan showed increased
-year survival time free of cardiovascular deaths compared
ith patients receiving placebo (32.3 months vs. 21.4
onths, respectively; log-rank: 18.2; p 0.0001) (Fig. 3A).
ospital admissions. Significantly fewer patients receiving
elmisartan were admitted to the hospital for CHF: 56
33.9%) patients in the telmisartan group versus 92 (55.1%)
atients in the placebo group (p  0.0001). By contrast, the
umber of hospital admissions for acute nonfatal MI,
ombined end point, revascularization, and stroke did not
ignificantly differ between the 2 groups. Cox regression
nalysis showed that—after adjustment for clinical, echo-
ardiographic, and laboratory variables—treatment with
elmisartan was independently associated with reduction of
ospital admission for worsening of heart failure (HR: 0.38;
5% CI: 0.19 to 0.51; p  0.0001).
After Kaplan-Meier analyses, the telmisartan group
howed increased 3-year mean survival time free of CHF
ospital admissions compared with patients receiving pla-
ebo (33.3 vs. 20.6 months, respectively; log-rank: 19.3; p
.0001) (Fig. 3B).
The beneficial effects of telmisartan were also evidenced
n patients treated with the combination of ACE-I and BB.
linical and echocardiographic analysis. At the time of
he last examination, more patients treated with telmisartan
ompared with placebo showed an improvement in NYHA
unctional class (37.4% vs. 32.6%) (p  0.001), and fewer
howed a deterioration (6.9% vs. 11.2%) (p  0.001).
Excluding the drop-out patients, a significant reduction
rom baseline of both systolic (118.3  7.2 mm Hg vs.
25.3  7.3 mm Hg; p  0.006) and diastolic (78.2  5.4
m Hg vs. 83.7  7.1 mm Hg; p  0.004) blood pressure
as observed in the telmisartan group during the first year
f treatment. Conversely, no significant decrease of either
ystolic or diastolic blood pressure was observed during the
ollowing 2 years.
As for heart rate, no significant differences from baseline
ere observed at the end of the follow-up in either group
67.1  8.8 beats/min vs. 65.7  7.9 beats/min in telmis-
rtan group; 68.5  8.4 beats/min vs. 69.3  8.1 beats/min
n the placebo group).
As for the echocardiographic evaluation, in the telmisar-
an group a significant decrease in LVDd as well as an
ncrease in LVEF were observed. In particular, such im-
rovement in left ventricle systolic function began within 6
onths, reached a plateau within 2 years, and persisted for
years in telmisartan compared with placebo patients,
rrespective of age, sex, etiology, NYHA functional classi-
cation, and co-treatment therapy.
Final echocardiographic changes between the 2 groups
ere: LVDd: 0.12  0.6 in telmisartan versus 0.04 
.3 (cm/m2) in placebo (p  0.0001); LVEF: 5.8  6.7%
n telmisartan versus 3.1  4.4% in placebo (p  0.0001).
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November 16, 2010:1701–8 Telmisartan in Hemodialysis Patients With CHFrop-out. The study drug was discontinued (Table 3)
ecause of adverse effects in 27 (16.3%) patients in the
elmisartan group and in 18 (10.7%) of the placebo group
p  0.01). We observed, among the drop-out patients,
ypotension in 18 patients (66.6%) and in 7 patients (40%)
f the respective groups. Among patients with hypotension,
3 of 18 in the telmisartan group and 4 of 7 in the placebo
roup were taking a combination of both ACE-I and BB.
An increase in plasma potassium leading to discontinua-
ion of the drug was observed in 5 cases (3%) in the
elmisartan group compared with 2 cases (1%) in the
lacebo group. Thirteen patients (4 in the telmisartan and 9
Figure 2 Kaplan-Meier Life-Table Analysis
for All-Cause Mortality
The cumulative 3-year mean survival time was 30.6 months in the
telmisartan group (solid line) and 24.2 months in the placebo group (dotted line).
Cox Proportional Hazards Regression AnalysisTable 2 Cox Proportional Hazards Regressio
Telmisartan (n 
End points
All-cause mortality 58
Hospital admission for CHF 56
All cardiovascular deaths 50
Nonfatal MI 4
Nonfatal stroke 2
Exploratory analyses
Pump failure deaths 34
Sudden cardiac death 12
Other cardiovascular deaths 4
Noncardiovascular deaths 7
Unknown cause of death 1
Permanent treatment withdrawals 26
Cox proportional hazards regression analysis showing the independ
adjustment for clinical, echocardiographic, and laboratory variables.
CHF  chronic heart failure; CI  confidence interval; HR  hazardvn the placebo group) were excluded from the study due to
rotocol violation or other nonmedical reasons.
iscussion
he results of our trial demonstrate that the addition of
elmisartan (titrated up to 80 mg, as tolerated) to standard
eart failure medications, including ACE-I and often BB,
n hemodialysis patients with CHF and LVEF 40%
ecreases the risk of all-cause and cardiovascular death as
ell as hospital stay for CHF decompensation.
Such beneficial effects of telmisartan were evident within
months from the beginning of the treatment and persisted
or the entire treatment period.
To the best of our knowledge, our results are the first to
rovide evidence that the addition of an ARB, namely
elmisartan, to regimens including various combination of
CE-I, digitalis, and BB is feasible and beneficial in ESRD
atients with CHF receiving dialysis treatment.
The patient population analyzed in the present study is
epresentative in terms of demography and comorbidity of
he “real world” of CHF hemodialyzed patients (Table 1).
lthough the mean age in the cohort is not so advanced
62.9  14.7 years), the female sex is well-represented
46.1%). All patients present a moderate-to-severe reduc-
ion in LVEF (mean 30%). In addition, ischemic etiology of
HF was confirmed in more than 55% in both arms of the
tudy (positive clinical history for MI). A higher prevalence
f diabetes (approximately 30%) has been found in our
opulation compared with the entire population in the
uropean Clinical Database (18.6%) (16) or in the Italian
emodialysis Registry (13.8%) (17). Furthermore, all
SRD patients were on a 4/week hemodialysis treatment,
hich is the standard medication administered to our CHF
ubjects.
Another significant feature is that the blood pressure
alysis
Placebo (n  167) HR (95% CI) p Value
91 0.51 (0.32–0.82) 0.004
92 0.38 (0.19–0.51) 0.00007
73 0.42 (0.38–0.61) 0.00009
5 0.81 (0.61–1.2) 0.5
4 0.72 (0.55–1.1) 0.4
52 0.45 (0.25–0.66) 0.0004
18 0.53 (0.33–0.68) 0.008
3 0.85 (0.62–1.1) 0.22
15 0.65 (0.43–0.9) 0.02
3 0.82 (0.55–1) 0.8
16 1.3 (1.1–1.6) 0.008
fects of treatment with telmisartan in the study population, after
I  myocardial infarction.n An
165)
ent efalues of patients were mainly under control at enrollment.
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Telmisartan in Hemodialysis Patients With CHF November 16, 2010:1701–8his point is particularly important to evaluate this treat-
ent in daily practice, especially with regard to adverse
ffects such as hypotension. In our study, drop-out percent-
ge for hypotension (16.3% in the telmisartan group vs.
0.7% in the placebo group) was significantly lower than
hat reported in dialysis guidelines (18). This might be
ecause the telmisartan target dose was reached during an
p-titration phase, similar to the one used in BB therapy.
However, most drop-out patients were taking a combi-
ation of ACE-I and BB at the start of the trial. The
ombination of telmisartan with both ACE-I and BB in
his subgroup of patients was associated with a significant
ncrease in hypotension leading to discontinuation of the
rug.
All enrolled patients, at the recruitment stage, were
lready being treated in accordance with the K-DOQI
ecommendations (19) for CHF hemodialysis patients. All
ubjects were receiving an ACE-I, and more than 60% also
Figure 3 Kaplan-Meier Life-Table Analysis for Cardiovascular M
Cumulative 3-year survival time free of cardiovascular deaths (A) and hospital adm
in patients treated with telmisartan (solid line) or placebo (dotted line). CHF  ch
dverse Events in Overall Study PopulationTable 3 Adverse Events in Overall Study Population
Telmisartan
(n  165)
Placebo
(n  167) p Value
Total adverse events 27 (16.3) 18 (10.7) 0.01
Hypotension 18 (66.6) 7 (38.9) 0.005
Increase in plasma potassium 5 (18.6) 2 (11.1) NS
Diarrhea 4 (14.8) 3 (16.7) NS
Dizziness 0 2 (11.1) NS
Back pain 0 2 (11.1) NS
Sore throat 0 2 (11.1) NSaalues given are n (%).ad a BB in both arms in their therapeutic schedule. The
bility of these drugs to reduce both mortality and morbidity
n the general CHF population has already been demon-
trated. In the case of hemodialysis patients with CHF, only
B (15,20) has shown similar effects. Therefore, the signif-
cant reduction in global mortality, which was based on a
ubstantial decrement in cardiovascular death after the
ddition of telmisartan, seems to have introduced an addi-
ional and not a substitute advantage. These observations
einforce the need of a multi-treatment for all CHF patients
ith low LVEF, if the goal is to achieve the lowest possible
orbidity and mortality rates.
Very few data exist from trials with ARB on hemodyal-
zed patients, and most trials have been conducted on a
mall cohort of hypertensive patients, often in an open-label
ashion (21,22). Fewer data are available for hemodyalized
atients with CHF.
Although a comparison of our data with those reported
rom other trials using an ARB in non-CHF or nonuremic
atients might be difficult, some observations are needed. In
he Val-HeFT (Valsartan Heart Failure Trial) and CHARM
Candesartan in Heart Failure to Affect Reduction in Morbid-
ty and Mortality) study, all-cause mortality did not decrease
benefits included only a decrease of hospital stays in the first
tudy and also of cardiovascular mortality in the second).
ll-cause mortality significantly decreased only in the sub-
roup of the patients of the CHARM study with ejection
raction 40% (23).
Conversely, in our cohort, characterized by high mortality
ty and CHF Hospital Stay
s (B)
heart failure.ortali
ission
ronicnd morbidity rate, the addition of telmisartan to conven-
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November 16, 2010:1701–8 Telmisartan in Hemodialysis Patients With CHFional heart failure therapy produced a significant reduction
f each single pre-specified cardiovascular end point (all-
ause mortality, cardiovascular mortality, hospital stay for
HF). Moreover, the beneficial effects were linked up to a
tandard dosage of telmisartan (80 mg, if tolerated). Con-
ersely, in other ARB trials the beneficial effects were
btained at a higher dose than standard practice: 100 mg
osartan in the LIFE (Losartan Intervention For End-point
eduction in hypertension) study (24), 32 mg candesartan in
he CHARM trial (11), and 320 mg valsartan in the
alHeFT (10).
The ELITE II (Losartan Heart Failure Survival Study)
25) and Val-HeFT trials increased the possibility of a
egative outcome in CHF patients when losartan and
alsartan, respectively, were combined with a BB. Our
esults, in line with the CHARM-Added study, seem to
elieve such fears. Evidence that more than 60% of our
atients and more than 50% of the CHARM-Added (14)
opulation were beta-blocked compared with a relatively
ow 33% in the Val-HeFT study (10) considerably reassures
s about a possible danger due to this triple association
ACE-I, ARB, and BB) in CHF patients.
We strongly believe that an effective antagonization of
he activated renin-angiotensin-aldosterone system (RAAS)
annot be reached by ACE-I therapy alone in hemodialyzed
atients.
The addition of an ARB to standard therapy leads to a
tronger antagonization of the activated RAAS, according
o our experience with hemodialyzed patients with CHF.
his is due to the different pharmacokinetics between
CE-I and ARBs in hemodialysis. The ACE-I are strongly
emoved by dialysis, whereas sartans—telmisartan among
hese—are not affected by this removal.
It is not surprising that limited data are available to
upport the use of ACE-I in ESRD patients receiving
ialysis (26). No article has been published thus far address-
ng the efficacy of ACE-I for established CHF in dialysis
atients. Despite this lack of data, the guidelines from the
ational Kidney Foundation Kidney Disease Outcomes
uality Initiative work group suggest that BB and ACE-I
hould be used in all ESRD patients receiving dialysis with
HF (19). These guidelines are based on limited data from
he ESRD population and are extended from data obtained
rom the general population. In fact, although BB efficacy
as been specifically tested in hemodialyzed patients with
HF—albeit in small trials (15,20)—ACE-I efficacy is not
nivocally accepted for this particular population.
Because the current therapeutic approach to CHF in the
eneral population mainly aimed at achieving maximal
AAS and sympathetic system inhibition, it is obviously
ased on the use of ACE-I and BB in association. But
CE-I are largely removed by dialysis, and the dosing
evealed to be effective to improve the outcome in non-
remic patients with CHF is hardly attainable in dialysis
27,28). mThe improvement of the LVEF and the favorable left
entricular remodelling in the arm treated with telmisartan
n our population support that evidence. The improvement
f LVEF certainly contributes significantly to the improve-
ent of the outcome, as seen in a previous study in a CHF
opulation (29). The plateau reached within 2 years might
e the consequence of the peculiar characteristics of our
tudy population.
The combination therapy with ACE-I and telmisartan
ffects also the NYHA functional class with significant
mprovement and less damage.
It is possible that the lower blood pressure values reached
n the telmisartan-treated group might also play a role in the
mprovement of morbidity and mortality, because optimal
lood pressure values are not well-established for hemodia-
yzed patients (30).
All things considered, the association of ACE-I and
RBs should always be used together with BB in the
herapy of hemodialyzed patients with CHF and should not
e limited to patients that still suffer from the symptoms
espite the use of ACE-I and BB, as CHF guidelines
uggest in non-ESRD patients.
tudy limitations. Although the sample size of the current
tudy is relatively small, it should be underlined that our
opulation represents a highly selected group of dialysis
atients with heart failure in advanced NYHA functional
lass, exhibiting a very high mortality and morbidity rate
despite routine medications and optimization of the dial-
sis regimen), as shown in the placebo group. In addition,
he high mortality rate exhibited by these patients per se
educes the sample size needed to achieve statistical
ignificance.
Another controversial aspect is that in our population the
aplan-Meier plots separate early, whereas neurohormonal
ntagonism usually takes months to show a difference. We
o not have a definite answer to this aspect. We could
ssume that in this specific population the beneficial effects
f telmisartan were in a first phase essentially due to a
emodynamic improvement and were also neurohormonal
nly after.
As for primary end points, our multivariable analyses
ere substantially exploratory, both for multiplicity of com-
arisons and high correlation among different end points.
s a result, some comparisons could be underpowered, due
o the low number of events.
Finally, the risk of hypotension might limit the applica-
ility of our study to all patients receiving dialysis. An
p-titration phase of telmisartan, similar to the one used in
B therapy, might increase the feasibility of this therapy.
onclusions
ur findings demonstrate that the ARB telmisartan signif-
cantly reduces all-cause mortality, cardiovascular death, and
ospital admission for decompensated heart failure in he-
odialysis patients with CHF and LVEF 40% when
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lthough further larger trials in hemodialyzed patients with
HF are desirable, our experience could offer clinicians an
pportunity to make additional improvements in the poor
rognosis of ESRD patients with CHF.
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APPENDIX
or the participating centers and researchers presently in charge,
lease see the online version of this article.
